Angiogenesis: CD-34 Cell Therapy: Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients with Myocardial Ischemia

Study of:
Safety of various doses of one’s own stem cells, delivered with a catheter (tube) into the regions of the heart with poor blood flow.

The purpose of this study is to determine the safety of various doses of one’s own stem cells, delivered with a catheter (tube) into the regions of the heart with poor blood flow. Stem cells are simple cells produced by bone marrow that can develop into blood cells or other types of cells. It is possible that these cells will grow into very small blood vessels that bring blood to the heart which may relieve chest pain. The CD34-Positive Cells will be taken from the body during a three-hour process called apheresis. Apheresis is similar to donating blood; however, only the part of the blood that is needed, the white blood cell component, is removed and the rest of the blood is returned to the body. The CD34-Positive Cells are delivered into the heart muscle during a cardiac catheterization. Study participants are required to follow up for clinic visits one week after the procedure and at months 1, 2, 3, 6, 9, and 12 following the procedure date. Three clinical sites will enroll 24 patients into this clinical trial.

Timothy D. Henry, MD, FACC

Randall K. Johnson, MD, FACC

Anil K. Poulose, MD, FACC

Jay H. Traverse, MD, FACC, FAHA

Karen L. Harvey, RN

Rachel Olson, RN, MS, CCRC

Dodie Walton, RN, CCRC

For more information about this study or other research studies at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Terri Streufert at 612-863-7821.